Nuvation Bio (NUVB) announced enrollment of the first patient into part 2 of G203, a global, randomized study evaluating the efficacy and safety of safusidenib versus placebo for the maintenance treatment of patients with high-grade IDH1-mutant astrocytoma following standard-of-care radiation or chemoradiation and adjuvant temozolomide. Safusidenib is a novel, oral, potent, brain-penetrant targeted inhibitor of mutant IDH1.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVB:
- Optimistic Buy Rating for Nuvation Bio Driven by Promising Prospects of Ibtrozi and Safusidenib
- Nuvation Bio enrolls first patient in TRUST-IV Phase 3 study of IBTROZI
- Nuvation Bio’s Strategic Growth Potential and Promising Pipeline Justify Buy Rating
- Nuvation Bio initiated with a Buy at Jefferies
- Nuvation Bio announces Japan MHLW approval for Ibtrozi